Gerd Fätkenheuer
University of Cologne
389 Papers
3.2K Citations
Gerd Fätkenheuer is an academic researcher from University of Cologne. The author has contributed to research in topics: Medicine & Viral load. The author has an hindex of 67, co-authored 369 publications. Previous affiliations of Gerd Fätkenheuer include University Hospital of Lausanne.
Chat about Author
Papers
Initiation of antiretroviral therapy in early asymptomatic HIV infection
Sean Emery,Shweta Sharma,Gerd Fätkenheuer,Josep M. Llibre,Jean-Michel Moli,Paula Munderi,Robin Wood,Karin L. Klingman,Simon Collins,H. Clifford Lane,Andrew N. Phil,James D. Neaton +11 more
TL;DR: The initiation of antiretroviral therapy in HIV-positive adults with a CD4+ count of more than 500 cells per cubic millimeter provided net benefits over starting such therapy in patients after the CD4+, but the risks of unscheduled hospital admissions were similar in the two groups.
CD4+ count-guided interruption of antiretroviral treatment.
Wafaa El-Sadr,Wafaa El-Sadr,Jens D Lundgren,James D. Neaton,Fred M. Gordin,Dominic Abrams,Roberto C. Arduino,Abdel Babiker,William J. Burman,Nathan Clumeck,Calvin J. Cohen,David V. Cohn,David A. Cooper,Janet Darbyshire,Sean Emery,Gerd Fätkenheuer,Brian Gazzard,Birgit Grund,Jennifer F Hoy,Karin L. Klingman,M. H. Losso,Norman Markowitz,Jacquie Neuhaus,Andrew N. Phillips,Claire Rappoport +24 more
TL;DR: Episodic antiretroviral therapy guided by the CD4+ count significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antireteviral therapy, largely as a consequence of lowering theCD4+ cell count and increasing the viral load.
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Vance G. Fowler,Helen W. Boucher,G. Ralph Corey,Elias Abrutyn,Adolf W. Karchmer,Mark E. Rupp,Donald P. Levine,Henry F. Chambers,Francis P. Tally,Gloria Vigliani,Christopher H. Cabell,Arthur Stanley Link,Ignace DeMeyer,Scott G. Filler,Marcus J. Zervos,Paul P. Cook,Jeffrey Parsonnet,Jack M. Bernstein,Connie S. Price,Graeme N. Forrest,Gerd Fätkenheuer,Marcelo Gareca,Susan J. Rehm,Hans Reinhardt Brodt,Alan D. Tice,Sara E. Cosgrove +25 more
TL;DR: Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis and met prespecified criteria for the noninferiority of daptomecin.
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
Jonathan A C Sterne,Margaret T May,Dominique Costagliola,Frank de Wolf,Andrew N. Phillips,Ross Harris,Michele Jonsson Funk,Ronald B. Geskus,John Gill,François Dabis,José M. Miró,Amy C. Justice,Bruno Ledergerber,Gerd Fätkenheuer,Robert S. Hogg,Antonella d'Arminio Monforte,Michael S. Saag,Colette Smith,Schlomo Staszewski,Matthias Egger,Stephen R. Cole +20 more
TL;DR: In this article, the CD4 cell count at which combination antiretroviral therapy should be started is examined in the absence of randomised trials in prospective cohort studies, and the effect of deferred initiation of combination therapy with immediate initiation on rates of AIDS and death, and on death alone, in adjacent CD4 cells ranges of width 100 cells per microL.
819
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Marina Caskey,Florian Klein,Julio C. C. Lorenzi,Michael S. Seaman,Anthony P. West,Noreen Buckley,Gisela Kremer,Lilian Nogueira,Malte Braunschweig,Johannes F. Scheid,Joshua A. Horwitz,Irina Shimeliovich,Sivan Ben-Avraham,Maggi Witmer-Pack,Martin Platten,Clara Lehmann,Leah A. Burke,Thomas Hawthorne,Robert J. Gorelick,Bruce D. Walker,Tibor Keler,Roy M. Gulick,Gerd Fätkenheuer,Sarah J. Schlesinger,Michel C. Nussenzweig +24 more
TL;DR: It is concluded that, as a single agent, 3BNC117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV- 1 prevention, therapy and cure.
757